Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01056679
• Date of registration: 08/09/2009
• Prospective Registration: Yes
• Primary sponsor: University of Cologne
• Public title: Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients AVD-Rev
• Scientific title: Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients
• Date of first enrolment: April 2010
• Target sample size: 30
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01056679
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

Germany

Contacts

• Name: Andreas Engert, Prof.
• Affiliation: University of Cologne

Key inclusion & exclusion criteria

Inclusion Criteria:

- Hodgkin Lymphoma, intermediate or advanced stage

- Age >60 and <75 years

- ECOG 2 or better

- No major organ dysfunction

- Ability to take aspirin or LMW Heparin

Exclusion Criteria:

- HL as composite lymphoma

- Prior use of lenalidomide

- Prior use of chemo- or radiotherapy



Age minimum: 60 Years
Age maximum: 75 Years
Gender: All

Health Condition(s) or Problem(s) studied

Hodgkin Lymphoma

Intervention(s)

Drug: Doxorubicine

Drug: Vinblastine

Drug: DTIC

Drug: Lenalidomide

Primary Outcome(s)

Dose limiting toxicities (DLT)

Secondary Outcome(s)

Overall response rate (ORR)

Progression free survival (PFS) [Time Frame: 2 years]

Secondary ID(s)

AVD-Rev

Source(s) of Monetary Support

Please refer to primary and secondary sponsors